|
CLASP2 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.63025148935958E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
6.72462086015457E-13 |
| Normal-vs-Stage2 |
5.32209999959399E-07 |
| Normal-vs-Stage3 |
5.93858295871996E-13 |
| Normal-vs-Stage4 |
8.50175485567206E-12 |
| Stage1-vs-Stage2 |
6.661000E-01 |
| Stage1-vs-Stage3 |
8.950000E-02 |
| Stage1-vs-Stage4 |
8.676400E-02 |
| Stage2-vs-Stage3 |
1.441640E-01 |
| Stage2-vs-Stage4 |
1.032570E-01 |
| Stage3-vs-Stage4 |
7.249600E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
6.66133814775094E-16 |
| Normal-vs-AfricanAmerican |
2.161700E-04 |
| Normal-vs-Asian |
3.49899997864611E-10 |
| Caucasian-vs-AfricanAmerican |
1.403240E-01 |
| Caucasian-vs-Asian |
9.738400E-01 |
| AfricanAmerican-vs-Asian |
1.803990E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
2.07611705604904E-13 |
| Normal-vs-Female |
1.76858527822787E-12 |
| Male-vs-Female |
6.438200E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.87340032375971E-10 |
| Normal-vs-Age(41-60Yrs) |
1.9684254226604E-13 |
| Normal-vs-Age(61-80Yrs) |
3.21020987570364E-12 |
| Normal-vs-Age(81-100Yrs) |
3.394000E-04 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
7.097800E-02 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
3.000000E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
5.223000E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
5.426400E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
9.620600E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
7.710400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.931780E-02 |
| Classical-VS-Follicular |
3.851600E-02 |
| Classical-VS-Other |
4.912400E-01 |
| Classical-VS-Normal |
1.64002145197628E-12 |
| Tall-VS-Follicular |
5.186700E-04 |
| Tall-VS-Other |
5.719000E-01 |
| Tall-VS-Normal |
4.11469747163551E-11 |
| Follicular-VS-Other |
4.473900E-02 |
| Follicular-VS-Normal |
2.25469999999284E-05 |
| Other-VS-Normal |
3.433100E-04 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.24356080988264E-12 |
| Normal-vs-N1 |
1.20980003792681E-10 |
| N0-vs-N1 |
2.740600E-01 |
|
|
